GI
BDRX

GAMMA Investing’s Biodexa Pharmaceuticals BDRX Stock Holding History

GAMMA Investing’s Portfolio BDRX Stock Details BDRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.5K Sell
1,203
-1,553
-56% -$5.24K ﹤0.01% 3610
2026
Q1 		$8.52K Buy
2,756
+2,401
+676% +$16.9K ﹤0.01% 3155
2025
Q4 		$4.03K Buy
355
+85
+31% +$2.42K ﹤0.01% 3372
2025
Q3 		$8.99K Buy
270
+31
+13% +$1.11K ﹤0.01% 2933
2025
Q2 		$10.3K Buy
239
+210
+724% +$13.4K ﹤0.01% 2784
2025
Q1 		$1.88K Buy
+29
New +$5.07K ﹤0.01% 3430
2024
Q4 		– Hold
0
– -$81 – 3784
2024
Q3 		– Sell
-3
Closed -$2.3K – 3561
2024
Q2 		$3.49K Sell
3
-6
-67% -$7.86K ﹤0.01% 2693
2024
Q1 		$18K Buy
9
+8
+800% +$15.8K ﹤0.01% 1722
2023
Q4 		$1.67K Buy
+1
New +$4.25K ﹤0.01% 2635

Other funds holding BDRX

APW
Allied Private Wealth Boca Raton, Florida $156M AUM
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
HHCP
Hilton Head Capital Partners Hilton Head Island, South Carolina $198M AUM
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

GAMMA Investing's BDRX Position: Q2 2026 in Review

GAMMA Investing reduced its Biodexa Pharmaceuticals (BDRX) stake by 56% in Q2 2026, selling an estimated $5.24K and leaving 1,203 shares worth $3.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3610.

GAMMA Investing first reported a position in BDRX in Q4 2023 and has held it in 9 quarters since. The position peaked at $18K in Q1 2024. 7 funds tracked by Wall St. Rank hold BDRX as of Q2 2026.

  • GAMMA Investing held 1,203 shares of Biodexa Pharmaceuticals worth $3.5K as of Q2 2026.
  • GAMMA Investing sold 1,553 Biodexa Pharmaceuticals shares in Q2 2026, an estimated $5.24K.
  • Biodexa Pharmaceuticals made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3610 holding.
  • GAMMA Investing first reported a position in Biodexa Pharmaceuticals in Q4 2023 and has held it in 9 quarters since.
  • GAMMA Investing's Biodexa Pharmaceuticals position peaked at $18K in Q1 2024.
  • 7 funds tracked by Wall St. Rank held Biodexa Pharmaceuticals as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.